Inhaled Tobramycin Dose and Systemic Absorption in Lung Transplant Recipients Without Cystic Fibrosis
LTRs without CF commonly had systemic tobramycin exposure during inhaled therapy. The 300 mg dose was linked to higher serum concentrations, supporting reduced dosing and active serum concentration monitoring to enhance safety.
Authors
- Michael D. Nailor (ORCID: https://orcid.org/0000-0003-4076-5748)
- Kellie J. Goodlet (ORCID: https://orcid.org/0000-0002-9736-0891)
- Sofya Tokman (ORCID: https://orcid.org/0000-0003-2821-8776)
- Christine Pham (ORCID: https://orcid.org/0000-0002-7155-5850)
- Amanda Hodges
Institutions
- Midwestern University (US)
- St. Joseph's Hospital and Medical Center (US)
- Dignity Health (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1111/tid.70158
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00